Synergistic effect of avenanthramides and cisplatin co-treatment in Ehrlich ascites carcinoma-bearing mice

• DOI: 10.21608/jmals.2023.315836
• Publication Date: 2023-09-09T06:06:14Z
• Authors: Karim El-Said; Areeg Elrahmawy; Hamed Abosharaf
• Keywords: Ehrlich ascites carcinoma

Chemotherapeutic drugs for cancer treatment cause several side effects.Natural-derived constituents as anticancer agents are effective against various types.This study addressed the synergistic effect of co-treatment with avenanthramides (AVNS) and cisplatin (Cis) in Ehrlich ascites carcinoma-bearing mice.Seventy mice were divided into seven groups (n = 10) follows: Gp1 was used a negative control, from Gp2 to Gp7 inoculated 1 × 10 6 EAC-cells/mouse, then left EAC-bearing mice, Gp3 injected Cis (2 mg/kg), Gp4 AVNS (50 ng/kg), Gp5 co-treated Gp4.Gp6 low dose (0.5 Gp6 Gp4.The body weight change percentages (b.wt%) calculated.On day 14, all sacrificed, ascitic fluids harvested, total tumor volume, count, live dead cells measured.The relative expression P53, Bcl-2, BAX, caspase-9 genes determined EAC-cells by RT-PCR.Sera samples collected biochemical parameters assessment.Liver tissues determination oxidants/antioxidants biomarkers.The results showed that high or doses led effects via targeting apoptosis can significantly inhibit growth, decrease liver dysfunctions induced Cis, enhance hepatic antioxidant status.